 Retinoblastoma Binding Proteins
"Retinoblastoma Binding Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of endogenous regulatory proteins that associate with RETINOBLASTOMA PROTEIN via a specific high-affinity binding domain. Members of this family of proteins are often found associated with histone-modifying enzymes and protein complexes that regulate gene expression.
| Descriptor ID |
D056286
|
| MeSH Number(s) |
D12.644.360.024.328 D12.776.157.057.158 D12.776.476.024.420 D12.776.660.769
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Retinoblastoma Binding Proteins".
Below are MeSH descriptors whose meaning is more specific than "Retinoblastoma Binding Proteins".
This graph shows the total number of publications written about "Retinoblastoma Binding Proteins" by people in this website by year, and whether "Retinoblastoma Binding Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 1 | 2 | 3 | | 2019 | 1 | 0 | 1 | | 2020 | 0 | 1 | 1 | | 2021 | 1 | 1 | 2 | | 2024 | 1 | 1 | 2 | | 2025 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Retinoblastoma Binding Proteins" by people in Profiles.
-
Patel R, Fountzilas C, Horowitz M, Schultz E, Clayback KM, Knudsen ES, Witkiewicz AK, Onel K. Pancreatic adenocarcinoma in a patient with a germline RB1 pathogenic variant. Fam Cancer. 2025 May 26; 24(2):46.
-
Broderick A, Pan E, Li J, Chu A, Hwang C, Barata PC, Cackowski FC, Labriola M, Ghose A, Bilen MA, Kilari D, Thapa B, Piero M, Graham L, Tripathi A, Garje R, Koshkin VS, Hernandez E, Dorff TB, Schweizer MT, Alva AS, McKay RR, Armstrong AJ. Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer. Prostate Cancer Prostatic Dis. 2025 Jun; 28(2):419-426.
-
Plimack ER, Tangen C, Plets M, Kokate R, Xiu J, Nabhan C, Ross EA, Grundy E, Choi W, Dinney CPN, Lee IC, Fong M, Scott Lucia M, Daneshmand S, Theodorescu D, Goldkorn A, Lerner SP, Flaig TW, McConkey DJ. Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial. Eur Urol. 2024 Oct; 86(4):297-300.
-
Rajasekaran S, Siddiqui J, Rakijas J, Nicolay B, Lin C, Khan E, Patel R, Morris R, Wyler E, Boukhali M, Balasubramanyam J, Ranjith Kumar R, Van Rechem C, Vogel C, Elchuri SV, Landthaler M, Obermayer B, Haas W, Dyson N, Miles W. Integrated multi-omics analysis of RB-loss identifies widespread cellular programming and synthetic weaknesses. Commun Biol. 2021 08 17; 4(1):977.
-
Pearson JD, Huang K, Pacal M, McCurdy SR, Lu S, Aubry A, Yu T, Wadosky KM, Zhang L, Wang T, Gregorieff A, Ahmad M, Dimaras H, Langille E, Cole SPC, Monnier PP, Lok BH, Tsao MS, Akeno N, Schramek D, Wikenheiser-Brokamp KA, Knudsen ES, Witkiewicz AK, Wrana JL, Goodrich DW, Bremner R. Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. Cancer Cell. 2021 08 09; 39(8):1115-1134.e12.
-
Knudsen ES, Nambiar R, Rosario SR, Smiraglia DJ, Goodrich DW, Witkiewicz AK. Pan-cancer molecular analysis of the RB tumor suppressor pathway. Commun Biol. 2020 04 02; 3(1):158.
-
Knudsen ES, Pruitt SC, Hershberger PA, Witkiewicz AK, Goodrich DW. Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy. Trends Cancer. 2019 05; 5(5):308-324.
-
Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017 12; 17(12):725-737.
-
Kamihara J, Bourdeaut F, Foulkes WD, Molenaar JJ, Mossé YP, Nakagawara A, Parareda A, Scollon SR, Schneider KW, Skalet AH, States LJ, Walsh MF, Diller LR, Brodeur GM. Retinoblastoma and Neuroblastoma Predisposition and Surveillance. Clin Cancer Res. 2017 07 01; 23(13):e98-e106.
-
Stein CK, Pawlyn C, Chavan S, Rasche L, Weinhold N, Corken A, Buros A, Sonneveld P, Jackson GH, Landgren O, Mughal T, He J, Barlogie B, Bergsagel PL, Davies FE, Walker BA, Morgan GJ. The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma. Oncotarget. 2017 Apr 25; 8(17):27854-27867.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|